Advances in Pharmacogenetics of Topical Therapies for Psoriasis

Abstract

Abstract: Psoriasis is an inflammatory hyperproliferative skin disease with a strong genetic susceptibility and influenced by genetic, immunological and environmental factors. Because the topical treatment is characterized of low cost, proper efficiency and high safety , it is commonly selected for most patients with mild to moderate psoriasis. However, the pharmacogenetics studies on the topical treatment are sparse. This review summarizes the correlations between genetic factors and topical agents to provide the theoretical guidance for the personalized medication in psoriasis.

Key words: Psoriasis, Pharmacogenetics, Vitamin D, Coal tar, Dithranol, Photochemotherapy

CLC Number:

R968

MENG Xiang-guang, LI Zhi, WANG Xian-meng, ZHOU Hong-hao. Advances in Pharmacogenetics of Topical Therapies for Psoriasis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1179-1184.

References

[1] 张学军. 全基因组关联分析对银屑病遗传学研究的启示[J]. 浙江大学学报(医学版),2009,38(4): 333-337.
[2] Henseler T, Christophers E.Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris[J].J Am Acad Dermatol,1985,13(3): 450-456.
[3] Lebwohl M.Psoriasis[J].Lancet,2003,361(9364): 1197-1204.
[4] Yip SY.The prevalence of psoriasis in the Mongoloid race[J].J Am Acad Dermatol,1984,10(6): 965-968.
[5] Braathen LR, Botten G, Bjerkedal T.Prevalence of psoriasis in Norway[J].Acta Derm Venereol Suppl (Stockh),1989,142: 5-8.
[6] Zhang XJ, Huang W, Yang S, et al.Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21[J].Nat Genet,2009,41(2): 205-210.
[7] Duffy DL, Spelman LS, Martin NG.Psoriasis in Australian twins[J].J Am Acad Dermatol,1993,29(3): 428-434.
[8] O'Rielly DD, Rahman P. Pharmacogenetics of psoriasis[J].Pharmacogenomics,2011,12(1): 87-101.
[9] 张伟,贺毅憬,周宏灏. 有机阴离子转运多肽1B1的遗传药理学进展[J]. 中国临床药理学与治疗学,2008,13(7): 721-729.
[10] 单婷婷,董瑞华,秦小清,等. 药物基因多态性与个体化用药的研究进展[J]. 医药导报,2010,29(1): 64-67.
[11] Nagpal S, Na S, Rathnachalam R.Noncalcemic actions of vitamin D receptor ligands[J].Endocr Rev,2005,26(5): 662-687.
[12] 冯建兵,王淑琴,彭媛香,等. 卡泊三醇软膏联合糠酸莫米松乳膏治疗寻常型银屑病60例[J]. 医药导报,2011,30(12): 1565-1567.
[13] Chen ML, Perez A, Sanan DK, et al.Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3[J].J Invest Dermatol,1996,106(4): 637-641.
[14] Ryan C, Menter A, Warren RB.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis[J].Mol Diagn Ther,2010,14(2): 81-93.
[15] Uitterlinden AG, Fang Y, Van Meurs JB, et al.Genetics and biology of vitamin D receptor polymorphisms[J].Gene,2004,338(2): 143-156.
[16] Kostner K, Denzer N, Muller CS, et al.The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature[J].Anticancer Res,2009,29(9): 3511-3536.
[17] Halsall JA, Osborne JE, Potter L, et al.A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma[J].Br J Cancer,2004,91(4): 765-770.
[18] Halsall JA, Osborne JE, Pringle JH, et al.Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis[J].Pharmacogenet Genomics,2005,15(5): 349-355.
[19] Saeki H, Asano N, Tsunemi Y, et al.Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris[J].J Dermatol Sci,2002,30(2): 167-171.
[20] Dayangac-Erden D, Karaduman A, Erdem-Yurter H.Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients[J].Arch Dermatol Res,2007,299(10): 487-491.
[21] Kontula K, Valimaki S, Kainulainen K, et al.Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol[J].Br J Dermatol,1997,136(6): 977-978.
[22] Lee DY, Park BS, Choi KH, et al.Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients[J].Arch Dermatol Res,2002,294(1/2): 1-5.
[23] Mee JB, Cork MJ.Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis[J].J Invest Dermatol,1998,110(3): 301-302.
[24] Piacentini S, Polimanti R, Porreca F, et al.GSTT1 and GSTM1 gene polymorphisms in European and African populations[J].Mol Biol Rep,2011,38(2): 1225-1230.
[25] Klautau-Guimaraes MD, Hiragi CD, D'Ascencao RF, et al. Distribution of glutathione S-transferase GSTM1 and GSTT1 null phenotypes in Brazilian Amerindians[J].Genetics and molecular biology,2005,28(1): 32-35.
[26] Gabbani G, Pavanello S, Nardini B, et al.Influence of metabolic genotype GSTM1 on levels of urinary mutagens in patients treated topically with coal tar[J].Mutat Res,1999,440(1): 27-33.
[27] 陈周,张建中. 寻常型银屑病的外用药物[J]. 中国药物应用与监测,2005,2(5): 34-37.
[28] Koczan D, Guthke R, Thiesen HJ, et al.Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules[J].Eur J Dermatol,2005,15(4): 251-257.
[29] 杨宝琦,赵娜,张福仁. 银屑病光疗和光化学疗法的研究进展[J]. 中华皮肤科杂志,2005,38(3): 195-197.
[30] Ryan C, Moran B, Mckenna MJ, et al.The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland[J].Arch Dermatol,2010,146(8): 836-842.
[31] Osmancevic A, Landin-Wilhelmsen K, Larko O, et al.Vitamin D production in psoriasis patients increases less with narrowband than with broadband ultraviolet B phototherapy[J].Photodermatol Photoimmunol Photomed,2009,25(3): 119-123.
[32] Ryan C, Renfro L, Collins P, et al.Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis[J].Br J Dermatol,2010,163(5): 1056-1063.